Vanessa Langness had always been a bit worried about the chemicals she worked with as a biomedical researcher, but when she got pregnant in October, her concerns grew.
Q&A: How argenx’s CEO plans to create a sequel to Vyvgart (and beat the IRA)
Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS